Premium
Metabolomics of prostate cancer
Author(s) -
Berger Alvin,
McCreedy Bruce,
Chinnaiyan Arul M.
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.a768-c
Subject(s) - prostate cancer , prostate , prostate biopsy , medicine , prostatectomy , urea cycle , biopsy , urology , rectal examination , pyrimidine metabolism , urine , cancer , chemistry , purine , amino acid , biochemistry , arginine , enzyme
Biomarkers for predicting whether subjects with elevated PSA should be monitored or have a prostate biopsy would reduce numbers of unnecessary biopsies. Biomarkers predictive of localized versus aggressive prostate tumors would better guide treatment decisions in biopsy‐confirmed prostate cancer. Global metabolomics was thus used to discover biomarkers for discriminating between: localized prostate tumors (PCa), metastatic prostate tumors (Met), and benign adjacent prostate tissue (N) by analyzing tissue following prostatectomy (study 1); and prostate cancer from benign prostate conditions by analyzing plasma and spun urine obtained post‐digital rectal exam (study 2). Subjects in both studies had elevated PSA and Gleason scores. Number of peaks in prostate, plasma, and urine were 432, 372, and 423, respectively. Comparing PCa/N, Met/N, Met/PCa (study 1), plasma GS major 4+/0, and urine GS major 4+/0, numbers of total peaks changed (q<0.1 study 1, q<0.2 study 2) were: 124, 403, 389, 48, and 200, respectively. Significantly changed peaks were linked to pathways including: urea cycle and metabolism of amino groups, purine metabolism, pyrimidine metabolism, glycine, serine and threonine metabolism, glutamate metabolism, glutathione metabolism, and citrate cycle. Further biological interpretations will be presented. Funded by NCI‐EDRN U01CA084986 and NCI‐SBIR HHSN261200633002C.